Literature DB >> 20953310

The Impact of Gamma Hydroxybutyrate (GHB) Legal Restrictions on Patterns of Use: Results from an International Survey.

Ib Anderson, Sy Kim-Katz, Je Dyer, Pd Blanc.   

Abstract

AIMS: To conduct an Internet-based survey of GHB use, identifying differences by respondent residence.
METHODS: We recruited GHB-knowledgeable persons via "social networking Internet sites." Individuals (n=314) or groups (n=66) were approached based on GHB-use testimonials. DATA COLLECTED: location, use, reason for cessation (if applicable).
FINDINGS: We recruited 155 GHB users. U.S. respondents (53 of 70; 76%) compared to non-U.S. respondents (38 of 85; 45%) were older and more highly educated (p<0.05) but manifest a 3-fold greater adjusted odds of GHB cessation (Odds Ratio [OR] 3.1; 95% CI 1.4-6.9; p < 0.05). Of the 80 respondents stating reason for cessation, 36 (45%) cited legal risk, price, or access; 44 (55%) cited health or related concerns. U.S. compared to non-U.S. respondents more frequently invoked legal and related concerns (OR 2.5; 95% CI 0.99-6.3; p=0.05). In a nested analysis, narrowly stated legal (n=4/5 U.S.) versus health (n=6/18 U.S.) reasons differed by location (p=0.048, one-tailed).
CONCLUSIONS: In the U.S., where GHB has stricter legal penalties, GHB cessation is more likely, with legal and related reasons more commonly invoked for cessation. These findings support a link between declining U.S. GHB abuse and more stringent restrictions; although other un-assessed factors may also explain this association. The Impact of Gamma Hydroxybutyrate (GHB) Legal Restrictions on Patterns of Use: Results from an International Survey.

Entities:  

Year:  2010        PMID: 20953310      PMCID: PMC2953864          DOI: 10.3109/09687630902729594

Source DB:  PubMed          Journal:  Drugs (Abingdon Engl)        ISSN: 0968-7637


  31 in total

1.  A pilot study using the internet to study patterns of party drug use: processes, findings and limitations.

Authors:  Peter G Miller; Jennifer Johnston; Paul R McElwee; Rick Noble
Journal:  Drug Alcohol Rev       Date:  2007-03

2.  [GHB, GBL and butanediol poisonings--a serious problem in Western Sweden].

Authors:  Kai Knudsen; Joachim Greter; Mario Verdicchio; Thomas Cederquist
Journal:  Lakartidningen       Date:  2005 Nov 7-13

3.  Adverse events, including death, associated with the use of 1,4-butanediol.

Authors:  D L Zvosec; S W Smith; J R McCutcheon; J Spillane; B J Hall; E A Peacock
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

4.  Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD).

Authors:  D M Wood; C Warren-Gash; T Ashraf; S L Greene; Z Shather; C Trivedy; S Clarke; J Ramsey; D W Holt; P I Dargan
Journal:  QJM       Date:  2008-01

Review 5.  Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate.

Authors:  Robert B Palmer
Journal:  Toxicol Rev       Date:  2004

6.  High mortality rates among GHB abusers in Western Sweden.

Authors:  Kai Knudsen; Joachim Greter; Mario Verdicchio
Journal:  Clin Toxicol (Phila)       Date:  2008-03       Impact factor: 4.467

7.  Area-level socioeconomic status in relation to outcomes in gamma-hydroxybutyrate intoxication.

Authors:  Ilene B Anderson; Susan Y Kim-Katz; Jo Ellen Dyer; Gillian E Earnest; John P Lamb; Paul D Blanc
Journal:  Clin Toxicol (Phila)       Date:  2009-01       Impact factor: 4.467

8.  Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions.

Authors:  James K Cunningham; Lon-Mu Liu
Journal:  Addiction       Date:  2003-09       Impact factor: 6.526

9.  Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia.

Authors:  David G E Caldicott; Fiona Y Chow; Brian J Burns; Peter D Felgate; Roger W Byard
Journal:  Med J Aust       Date:  2004-09-20       Impact factor: 7.738

10.  Pseudoephedrine legislation decreases methamphetamine laboratory-related burns.

Authors:  Bridget A Burke; Robert W Lewis; Barbara A Latenser; Joseph Y Chung; Clark Willoughby
Journal:  J Burn Care Res       Date:  2008 Jan-Feb       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.